GCG and glucose metabolism disease: In conclusion, this study has delineated a previously unappreciated mechanism by which CPS1 modulates glucagon-induced hepatic gluconeogenesis through the CaMKII/FOXO1 signaling cascade and offered a potential natural inhibitor of CPS1, which may show therapeutic benefits in the management of glucose metabolism disorders.